Madrigal Pharmaceuticals, Inc. MDGL Long-term debt, gross
Long-term debt, gross at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtInstrumentCarryingAmount.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s long-term debt, gross.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s long-term debt, gross?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported long-term debt, gross of $478.89M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s long-term debt, gross changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s long-term debt, gross increased by 227.2% year-over-year, from $146.36M to $478.89M.